Edition:
United States

Eisai Co Ltd (ESALY.PK)

ESALY.PK on OTC Markets Group

51.54USD
18 Aug 2017
Change (% chg)

$-0.18 (-0.35%)
Prev Close
$51.72
Open
$51.58
Day's High
$51.58
Day's Low
$51.45
Volume
1,877
Avg. Vol
3,493
52-wk High
$66.38
52-wk Low
$51.05

Latest Key Developments (Source: Significant Developments)

FDA approves Eisai's Fycompa for use as monotherapy for the treatment of partial-onset seizures
Wednesday, 26 Jul 2017 06:41pm EDT 

July 26 (Reuters) - Eisai Co Ltd <4523.T>:FDA approves Eisai's Fycompa® (perampanel) for use as monotherapy for the treatment of partial-onset seizures.Eisai - Fycompa approved for adjunctive use for pos and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.  Full Article

Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma
Tuesday, 25 Jul 2017 07:55am EDT 

July 25 (Reuters) - Eisai Co Ltd <4523.T>::Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma.Eisai Inc - FDA submission is based on positive results of pivotal phase 3 reflect trial.  Full Article

R&I affirms Eisai's rating at "A+" and announces stable outlook -R&I
Friday, 30 Jun 2017 04:01am EDT 

June 30(Reuters) - Eisai Co Ltd <4523.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Rating outlook stable -R&I.  Full Article

Ewopharma announces commercial partnership with Eisai
Thursday, 22 Jun 2017 11:00am EDT 

June 22 (Reuters) - Ewopharma AG:Ewopharma announces commercial partnership with Eisai Co.Ewopharma says it will commercialise Halaven (eribulin mesylate) in nine countries within European Union and in two countries outside of EU.Ewopharma will also commercialise Targretin in Hungary and Poland as well as Zonegran in Hungary.Ewopharma says had acquired rights to commercialise several of Eisai's products in eleven countries in central and eastern Europe.  Full Article

Positive topline results show Eisai's Lenvatinib meets primary endpoint
Wednesday, 25 Jan 2017 08:00am EST 

Eisai Co Ltd <4523.T>: Positive topline results of large phase 3 trial show Eisai's lenvatinib meets primary endpoint in unresectable hepatocellular carcinoma . Eisai - trial achieved its primary endpoint . Eisai Co Ltd - clinically meaningful and statistically significant improvements for lenvatinib were achieved in progression-free survival .Eisai- lenvatinib is under investigation for unresectable hepatocellular carcinoma, safety/effectiveness of product for that use hasn't been established.  Full Article

Arena Pharma, EISAI announce FDA approval of BELVIQ XR extended-release tablets
Tuesday, 19 Jul 2016 08:26am EDT 

Arena Pharmaceuticals Inc : BELVIQ XR is expected to be available in fall of 2016. . Arena pharmaceuticals inc says in connection with approval, arena will receive a $10 million milestone payment. . EISAI Inc and Arena Pharmaceuticals announce FDA approval of Belviq XR (lorcaserin HCL) extended-release tablets .In connection with approval, arena will receive a $10 million milestone payment.  Full Article

Eisai, Arena announce regulatory approval of VENESPRI in Mexico
Thursday, 14 Jul 2016 08:05am EDT 

Arena Pharmaceuticals Inc : Eisai and Arena Pharmaceuticals announce regulatory approval of VENESPRI® (lorcaserin HCl) in Mexico . In connection with the approval, Arena will receive a $1 million milestone payment . In connection with the approval, Arena will receive a $1 million milestone payment .VENESPRI® is expected to become available later this year.  Full Article

R&I affirms Eisai‘s rating at "A+" and stable outlook
Friday, 8 Jul 2016 02:21am EDT 

Eisai Co Ltd <4523.T>: Says rating and Investment Information, Inc. (R&I) affirmed the rating on Eisai at "A+" .Rating outlook stable.  Full Article

Eisai and Novartis enter deal to co-promote Lenvima with Everolimus in U.S.
Thursday, 2 Jun 2016 04:15pm EDT 

Eisai Inc : Under terms , Novartis and Eisai sales representatives will promote availability of this combination regimen to oncologists nationwide .Eisai enters into a collaboration agreement to co-promote Lenvima (lenvatinib) in combination with Everolimus in the U.S..  Full Article

Six Japanese drugmakers will team up to discover new cancer, depression treatments - Nikkei
Wednesday, 25 May 2016 01:22pm EDT 

Nikkei: Astellas Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharmaceutical,Chugai Pharmaceutical will collaborate with 4 research institutions - Nikkei . The Six Drugmakers will work with research organizations providing cell, tissue samples to discover new pharmaceuticals - Nikkei . Around 3 billion Yen ($27.2 Million) will be put into drug-discovery efforts by fiscal 2019 - Nikkei .Group will create five teams looking into treatments for cancer, diabetic nephropathy and mental illnesses including depression - Nikkei.  Full Article

BRIEF-FDA approves Eisai's Fycompa for use as monotherapy for the treatment of partial-onset seizures

* FDA approves Eisai's Fycompa® (perampanel) for use as monotherapy for the treatment of partial-onset seizures